254 related articles for article (PubMed ID: 30727940)
1. Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours.
Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):98-106. PubMed ID: 30727940
[TBL] [Abstract][Full Text] [Related]
2. Nuclear Medicine in Patients with NET: Radiolabeled Somatostatin Analogues and their Brothers.
Cuccurullo V; Prisco MR; Di Stasio GD; Mansi L
Curr Radiopharm; 2017; 10(2):74-84. PubMed ID: 28332450
[TBL] [Abstract][Full Text] [Related]
3. State of the Art and Recent Developments of Radiopharmaceuticals for Pancreatic Neuroendocrine Tumors Imaging.
Carollo A; Papi S; Grana CM; Mansi L; Chinol M
Curr Radiopharm; 2019; 12(2):107-125. PubMed ID: 30843499
[TBL] [Abstract][Full Text] [Related]
4. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT.
Kulkarni HR; Baum RP
PET Clin; 2014 Jan; 9(1):83-90. PubMed ID: 25029937
[TBL] [Abstract][Full Text] [Related]
5. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
6. Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.
Teunissen JJ; Kwekkeboom DJ; Valkema R; Krenning EP
Endocr Relat Cancer; 2011 Oct; 18 Suppl 1():S27-51. PubMed ID: 22005114
[TBL] [Abstract][Full Text] [Related]
7. Nuclear Medicine Imaging of Neuroendocrine Tumors.
Brabander T; Kwekkeboom DJ; Feelders RA; Brouwers AH; Teunissen JJ
Front Horm Res; 2015; 44():73-87. PubMed ID: 26303705
[TBL] [Abstract][Full Text] [Related]
8. Experience with indium-111 and yttrium-90-labeled somatostatin analogs.
Virgolini I; Traub T; Novotny C; Leimer M; Füger B; Li SR; Patri P; Pangerl T; Angelberger P; Raderer M; Burggasser G; Andreae F; Kurtaran A; Dudczak R
Curr Pharm Des; 2002; 8(20):1781-807. PubMed ID: 12171531
[TBL] [Abstract][Full Text] [Related]
9. Gamma Emitters in Pancreatic Endocrine Tumors Imaging in the PET Era: Is there a Clinical Space for 99mTc-peptides?
Briganti V; Cuccurullo V; Di Stasio GD; Mansi L
Curr Radiopharm; 2019; 12(2):156-170. PubMed ID: 30827276
[TBL] [Abstract][Full Text] [Related]
10. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
11. Tumor imaging and therapy using radiolabeled somatostatin analogues.
de Jong M; Breeman WA; Kwekkeboom DJ; Valkema R; Krenning EP
Acc Chem Res; 2009 Jul; 42(7):873-80. PubMed ID: 19445476
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
13. Contemporary nuclear medicine imaging of neuroendocrine tumours.
Wong KK; Waterfield RT; Marzola MC; Scarsbrook AF; Chowdhury FU; Gross MD; Rubello D
Clin Radiol; 2012 Nov; 67(11):1035-50. PubMed ID: 22633086
[TBL] [Abstract][Full Text] [Related]
14. Preclinical studies of SPECT and PET tracers for NET.
Brom M; Boerman O; Gotthardt M; Oyen WJ
PET Clin; 2014 Jan; 9(1):63-9. PubMed ID: 25029935
[TBL] [Abstract][Full Text] [Related]
15. Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours.
Virgolini I; Gabriel M; Kroiss A; von Guggenberg E; Prommegger R; Warwitz B; Nilica B; Roig LG; Rodrigues M; Uprimny C
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2072-83. PubMed ID: 27174220
[TBL] [Abstract][Full Text] [Related]
16. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
Kwekkeboom DJ; de Herder WW; Krenning EP
Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
[TBL] [Abstract][Full Text] [Related]
17. Novel PET tracers: added value for endocrine disorders.
Bergeret S; Charbit J; Ansquer C; Bera G; Chanson P; Lussey-Lepoutre C
Endocrine; 2019 Apr; 64(1):14-30. PubMed ID: 30875057
[TBL] [Abstract][Full Text] [Related]
18. Receptor radionuclide targeting for neuroendocrine tumors (NET) diagnostic and therapy.
Vija L; Dierickx L; Courbon F
Ann Endocrinol (Paris); 2019 Jun; 80(3):166-171. PubMed ID: 31053248
[TBL] [Abstract][Full Text] [Related]
19. Nuclear medicine in NET.
Sorschag M; Malle P; Gallowitsch HJ
Wien Med Wochenschr; 2012 Oct; 162(19-20):416-22. PubMed ID: 22810487
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Ito T; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2017 Feb; 24(1):15-24. PubMed ID: 27875420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]